Floatz logo

Nintedanib

Pulmonary Fibrosis

Boehringer IngelheimSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Acetylcysteine
Boehringer Ingelheim
Phase 3BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Sildenafil
Alicia Gerke
Phase 3BB
Interferon Gamma-1B
NYU Langone Health
Phase 3BB

View all 34 →

Same molecule, other indications

Nintedanib is also rated in:

idiopathic pulmonary fibrosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →